Non-invasive breast cancer means abnormal cells have grown inside the breast’s milk ducts or lobules but have not spread into surrounding breast tissue. It is classified as Stage 0, the earliest possible stage, and accounts for roughly 20% to 25% of all new breast cancer diagnoses in the United States. The five-year relative survival rate for localized breast cancer, including Stage 0, is 99.6%.
How Non-Invasive Differs From Invasive
In a healthy breast, cells lining the milk ducts and lobules grow and replace themselves in an orderly way. In non-invasive breast cancer, cells inside those structures have become abnormal and multiplied, but they remain contained behind a natural boundary called the basement membrane. Think of it like mold growing inside a sealed pipe: the problem exists, but it hasn’t broken through to the surrounding tissue. Once abnormal cells push past that boundary into nearby breast tissue, the cancer is reclassified as invasive.
This distinction matters because non-invasive cancer cannot spread to lymph nodes or other organs. It stays put. That’s why survival rates are so high and treatment is generally less aggressive than for invasive disease.
The Two Main Types
Ductal Carcinoma in Situ (DCIS)
DCIS is by far the more common form. It starts in the milk ducts and is considered a direct precursor to invasive ductal carcinoma. If left completely untreated, studies estimate that 25% to 60% of DCIS cases would eventually progress to invasive cancer, though that progression typically takes 9 to 24 years. Because of this real but variable risk, most women with DCIS receive some form of treatment.
DCIS represents about 15% of all breast cancer diagnoses in the UK and an even larger share in countries with widespread mammography screening, since screening catches many cases that would otherwise go undetected for years.
Lobular Carcinoma in Situ (LCIS)
LCIS develops in the milk-producing lobules rather than the ducts. It behaves quite differently from DCIS. Only about 7% to 12% of women with pure LCIS go on to develop invasive cancer, and the invasive cancer that does appear isn’t always lobular. Roughly half the time it turns out to be ductal. Because of this, LCIS is viewed more as a risk marker than a true precursor. In the most recent cancer staging system (AJCC 8th Edition), LCIS was actually removed from formal staging altogether and reclassified as a benign finding. Most women with LCIS are offered increased monitoring rather than surgery or radiation.
How It’s Found
Non-invasive breast cancer rarely causes symptoms you can feel. There’s usually no lump, no pain, no skin changes. The vast majority of DCIS is picked up on a routine mammogram, which is one of the strongest arguments for regular screening.
On a mammogram, DCIS most often shows up as tiny calcium deposits called microcalcifications. The shape and arrangement of those deposits give radiologists important clues. Fine, linear calcifications that follow the path of a duct, or clusters arranged in a segmental pattern, are particularly suspicious. Linear and segmental distributions are associated with malignancy up to 80% of the time. LCIS, by contrast, is essentially invisible on imaging. It’s almost always found incidentally when a biopsy is done for another reason.
A mammogram alone can’t confirm the diagnosis. A biopsy is the only way to know for certain. The most common approach is a core needle biopsy, where a hollow needle removes a small cylinder of tissue after the area is numbed. When the suspicious area is only visible on imaging, the biopsy is guided in real time by mammography or ultrasound so the needle reaches the exact spot. In some cases of DCIS, surgery itself is needed to determine whether invasive cancer is also present, because a needle may sample only part of the affected area.
Treatment Options for DCIS
Because DCIS is the type that typically requires active treatment, the main decision comes down to how much tissue needs to be removed and whether radiation follows. Treatment has a high success rate, and in most cases the cancer is removed with a low chance of returning.
The most common path is a lumpectomy (removing the abnormal area plus a margin of healthy tissue) followed by radiation therapy. This preserves most of the breast. Research shows a slightly higher chance of the cancer returning after lumpectomy compared to mastectomy, but long-term survival rates between the two approaches are very similar. For women who prefer to avoid radiation or whose DCIS is widespread, removing the entire breast (mastectomy) is an option that eliminates almost all risk of recurrence on that side.
Some women are offered lumpectomy without radiation, particularly if the DCIS is small, low-grade, and was removed with wide clear margins. In certain situations, lumpectomy combined with hormone therapy is another choice. Radiation may not be possible for women in early pregnancy, those who have had prior chest radiation, or those with conditions that increase sensitivity to radiation side effects.
The Role of Hormone Therapy
Many DCIS tumors have receptors for estrogen, meaning the hormone fuels their growth. For these cases, hormone-blocking medication taken as a daily pill can reduce the risk of cancer returning or developing in the opposite breast. In clinical trials, this treatment cut the risk of new cancer in the opposite breast by 44%. However, the additional benefit on top of surgery and radiation is modest in absolute terms, reducing recurrence rates by about 2% to 4%. That means the decision to take it involves weighing a relatively small benefit against potential side effects like hot flashes, joint stiffness, and fatigue over several years of use.
Hormone therapy does not improve overall survival for DCIS. Its value is in lowering the odds of dealing with a future cancer event, not in changing the long-term outlook, which is already excellent.
Risk Factors
The risk factors for developing non-invasive breast cancer overlap heavily with those for invasive disease. Family history of breast cancer, use of hormone replacement therapy, and increasing age are all well-established contributors. Research comparing DCIS and LCIS found that the two types share very similar risk profiles, with two notable exceptions: longer duration of hormone replacement therapy and a stronger family history of breast cancer were more closely associated with LCIS than with DCIS.
Living With a Stage 0 Diagnosis
A non-invasive breast cancer diagnosis can feel confusing. It contains the word “cancer,” yet many women are told their prognosis is essentially the same as someone without cancer. Some researchers have even questioned whether DCIS should always be called cancer at all, given that a significant portion of cases would never progress to a life-threatening disease. That debate hasn’t changed clinical practice yet, but it does explain why you may hear the term “pre-cancer” used alongside “Stage 0 cancer.”
After treatment, follow-up typically includes regular mammograms and clinical breast exams to watch for any recurrence. Most recurrences, when they happen, are caught early and remain highly treatable. The key takeaway is that a non-invasive diagnosis carries an excellent outlook. Treatment is effective, options are well-studied, and the vast majority of women go on to live full, healthy lives after it.